Ligand Pharmaceuticals ( LGND Quick Quote LGND - Free Report) have gained 62.1% so far this year, primarily driven by its promising technology platforms that have helped develop promising new drugs. The Zacks Medical - Biomedical and Genetics industry has declined 19.6% in the same period. Image Source: Zacks Investment Research
Ligand’s top line is being driven by royalties from sales of drugs developed using its Captisol technology, including
Amgen’s ( AMGN Quick Quote AMGN - Free Report) blockbuster drug, Kyprolis, and Gilead’s ( GILD Quick Quote GILD - Free Report) COVID-19 drug, Veklury.
The surge in cases due to the Delta variant has been boosting demand for Gilead’s Veklury so far this year. Gilead recorded Veklury’s sales of $4.2 billion in the first nine months of 2021.
In the first nine months, sales of Amgen’s Kyprolis were driven by strong demand. Amgen’s Kyprolis is approved for treating multiple myeloma. Its sales totaled $824 million in the first nine months of 2021
The higher sales of these drugs have driven Ligand’s top line year to date. The prospects of GILD’s Veklury and AMGN’s Kyrpolis have been the primary driver of Ligand’s shares so far this year which is likely to continue in 2022.
The recent spike in COVID-19 infections amid the emergence of another deadly variant, Omicron, is likely to support the demand for Veklury going forward. Gilead raised revenue guidance for Veklury on its third-quarter earnings call by more than 60%, estimated at the midpoints of the earlier and updated guided range.
Moreover, momentum in Amgen’s Kyprolis sales is likely to continue on the back of potential label expansions.
The performance of these two drugs will be a major catalyst for Ligand’s shares going forward. We expect these drugs to continue driving Ligand’s stock next year.
Apart from Captisol, Ligand has another promising technology called OmniAb in its portfolio. It is newer than the Captisol technology and has longer patent protection as well. The first OmniAb-derived drug, Gloria Biosciences’ zimberelimab, received approval in China as a treatment for Hodgkin’s lymphoma in August. A few potential approvals for the partnered OmniAb-derived drugs are expected in the upcoming quarters.
Approvals to OmniAb-derived products will bring additional revenues for Ligand going forward, which may help propel the company’s shares higher. We note that Ligand is planning to spin off its OmniAb-related business into a separate company.
Ligand has several other promising technology platforms, which are also attracting collaboration agreements. Earlier this month, Ligand and
GlaxoSmithKline ( GSK Quick Quote GSK - Free Report) expanded their current agreement to include an additional neurological target.
Ligand and Glaxo entered into a collaboration in December 2020 to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases, using Ligand’s ion-channel-based discovery technology. These collaboration agreements and their expansion bring additional revenues in upfront payments. These agreements also represent future revenues in potential milestone payments.
Ligand currently carries a Zacks Rank #3 (Hold). You can see
. the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here